Pfizer’s vaccine, developed in collaboration with Germany’s BioNTech SE, has “an extraordinarily high degree of efficacy -- more than 90%, close to 95%," Fauci said in an interview.
That could be a key factor in overcoming reluctance to take pandemic vaccines that have been developed at top speed.“What I would hope is that even though there’s a degree of skepticism about vaccines in general, that when the general public sees how effective this vaccine is," said Fauci, director of the National Institute of Allergy and Infectious Diseases, “we might see a turnaround of the attitude toward vaccination."The U.S.
may begin offering the vaccine to priority groups at the end of December, Fauci said. It’s hoped to blunt spiking infections that.